Liquid biopsies in the era of immuno-oncology

This review, published in the Annals of Oncology, discusses the role of liquid biopsies in the field of immuno-oncology to predict response, relapse or adverse events in cancer patients treated with immunotherapy. A liquid biopsy is a test done on a sample of blood to look for cancer cells from a tumour that are circulating […]

read more

ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101

Results from the JAVELIN Renal 101 study to evaluate avelumab plus axitinib in untreated sarcomatoid renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Sarcomatoid differentiation can occur in all subtypes of renal cell carcinoma (RCC) and is an aggressive form of RCC. JAVELIN […]

read more

ESMO 2019: ADAPTeR study to evaluate the role of nivolumab before and after surgery – results of biomarker analysis

Results from the ADAPTeR study to evaluate the role of anti-PD1 checkpoint inhibitors before and after surgery in patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. ADAPTeR is a single centre study in which metastatic RCC patients were treated with […]

read more

Immune checkpoint inhibitors are more effective in PD-L1 positive patients

Immune checkpoint inhibitors, such as nivolumab, ipilimumab or pembrolizumab are often used alone or in combination with other drugs for the treatment of metastatic renal cell carcinoma (RCC). Unfortunately, researchers are yet to identify a reliable biomarker to predict a patient’s response to immune checkpoint inhibitors. PD-L1 is a potential biomarker for the effectiveness of […]

read more

The role of biomarkers in predicting response to treatment in metastatic kidney cancer

This review published in Clinical Genitourinary Cancer summarises the current treatments available for metastatic renal cell carcinoma (RCC), and the data from some of the most recent clinical trials, including CABOSUN, CheckMate 214, IMmotion151, and JAVELIN Renal 100. There is also a discussion about the use of biomarkers as predictors of outcomes for patients with […]

read more

PD-1 and CTLA-4 as biomarkers for survival in kidney cancer

A recent study published in Journal of Clinical Medicine last month provides evidence for the expression of PD-1 and CTLA-4 receptors on white blood cells (tumour-infiltrating mononuclear cells) to be associated with a worse overall survival in patient with renal cell carcinoma (RCC). The combination of PD-1 and CTLA-4 expression in tumour-infiltrating mononuclear cells might […]

read more

Genetic mutations associated with survival in immunotherapy-treated kidney cancer patients

A recent study of patients with solid tumours treated with immune checkpoint inhibitors has shown improved overall survival in patients who had mutations in the genes that code for a group of proteins involved in the way DNA is packaged in the cell (SWI and SNF genes, BRG1/hBRM-associated factor (BAF) and polybromo-BAF (PBAF)). The researchers […]

read more

ASCO 2019: Human endogenous retrovirus and efficacy of checkpoint inhibitors in kidney cancer

This paper was presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago earlier this week. Human endogenous retrovirus (hERV) is an ancient virus that is found in the human genome; about 8% of the human genome is hERV. HERVs have been inherited by successive generations and it is possible that […]

read more

ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study

Results from the biomarker analysis from the JAVALIN Renal 101 clinical trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago this week. JAVELIN Renal 101 compared the avelumab plus axitinib combination with sunitinib. There were 886 patients in the study, 442 received the combination and 444 received sunitinib. For […]

read more

Biomarkers for kidney cancer

This interview from Practice Update with Dr Neeraj Agarwal from the Hunstman Cancer Center, Salt Lake City, Utah, USA discusses current and potential biomarkers for renal cell carcinoma (RCC). The two most common models currently used in the clinic are the Memorial Sloan-Kettering (MSKCC) model and the International Metastatic Renal Cell Carcinoma Consortium (IMDC) model, […]

read more
Showing 11 to 20 of 52 results
  TOP